Clinical Trial Update: Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. [Phase 3]

View source ↗

Summary

Phase 3 clinical study evaluating LM-302 in combination with tislelizumab, and tislelizumab-based chemotherapy, for gastric or gastroesophageal junction adenoca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• LM-302
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Conditions: Adenocarcinoma | Phase 3 | Status: NOT_YET_RECRUITING